NYSE:ABTMedical Equipment
Abbott Laboratories (ABT) Stock Faces Margin Squeeze As Net Profit Slide Tests Growth Narrative
Abbott Laboratories (ABT) just posted Q2 2026 revenue of about US$12.6b with basic EPS of US$0.53, alongside trailing twelve month revenue of roughly US$46.6b and EPS of US$3.11. Over recent quarters the company has seen revenue move from about US$11.1b in Q2 2025 to US$12.6b in Q2 2026, while quarterly EPS shifted from US$1.02 to US$0.53. This sets up a results season where investors are likely to focus closely on how margins are holding up in the current mix of growth drivers.
See our full...